Can chemotherapy be omitted for patients with N0 or N1 endocrine-sensitive breast cancer treated with gonadotropin-releasing hormone agonist and tamoxifen?

PURPOSE: Whether administering chemotherapy followed by tamoxifen plus a gonadotropin-releasing hormone (GnRH) agonist to treat patients with lower-risk hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer provides a greater benefit than administerin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Juhyeon, Park, Chan Sub, Oh, Jeong Hun, Park, In-Chul, Seong, Min-Ki, Noh, Woo Chul, Kim, Hyun-Ah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Surgical Society 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333805/
https://www.ncbi.nlm.nih.gov/pubmed/37441320
http://dx.doi.org/10.4174/astr.2023.105.1.31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333805/
https://www.ncbi.nlm.nih.gov/pubmed/37441320
http://dx.doi.org/10.4174/astr.2023.105.1.31

Ejemplares similares